FDA has granted approval to test psilocybin in patients with treatment-resistant depression

 FDA has granted approval to test psilocybin in patients with treatment-resistant depression

The US Food and Drug Administration also known as FDA has granted approval to COMPASS Pathways' trial to test psilocybin in patients with treatment-resistant depression. This makes (ProCare / Chills and Thrills) incredibly happy and excited to see how they begin to notice a constant positive effect of the drug on patients' mood. Check out their article in the link below:

 https://compasspathways.com/news-views/#press-releases

Leave a reply